Organogenesis Holdings Inc.: Q4 and Full Year 2024 Financial Results
Canton, MA, February 27, 2025 – Organogenesis Holdings Inc., a pioneering company in the regenerative medicine and tissue innovations sector, recently announced its financial results for the fourth quarter and the year ended December 31, 2024. The company’s focus lies in the development, manufacturing, and sale of advanced wound care, surgical, and sports medicine products.
Financial Highlights
For the fourth quarter, Organogenesis reported total revenue of $128.1 million, marking a 14.2% increase compared to the same period in the previous year. Net income for the quarter came in at $15.5 million, a significant improvement from the $3.8 million in the same quarter the year before. For the full year 2024, the company reported total revenue of $459.9 million, representing a 10.1% year-over-year growth. Net income for the year was reported at $33.9 million, a substantial increase from the $16.1 million in the previous year.
Business Segment Performance
The Advanced Wound Care segment, which accounts for the majority of Organogenesis’ revenue, saw sales of $108.6 million in Q4 2024, a 14.8% increase from Q4 2023. The Surgical and Sports Medicine segment reported sales of $19.5 million, a 3.7% year-over-year growth.
Impact on Consumers
These financial results indicate the ongoing success and growth of Organogenesis in the regenerative medicine industry. As a consumer, this means that there will likely be continued advancements and innovations in wound care, surgical, and sports medicine products. This could lead to improved healing times, reduced scarring, and more effective treatments for various injuries and conditions.
Impact on the World
Organogenesis’ strong financial performance and commitment to research and development in the regenerative medicine sector can contribute significantly to the global healthcare industry. The ongoing advancements in tissue innovations and regenerative medicine have the potential to revolutionize patient care, particularly in the areas of wound care and surgical procedures. This could lead to improved patient outcomes, reduced healthcare costs, and a better quality of life for individuals around the world.
Conclusion
In conclusion, Organogenesis Holdings Inc.’s Q4 and full year 2024 financial results demonstrate the company’s growth and success in the regenerative medicine and tissue innovations sector. These advancements have the potential to positively impact consumers by providing improved healing solutions and innovations in wound care, surgical, and sports medicine. Furthermore, the global healthcare industry could benefit from Organogenesis’ commitment to research and development in tissue innovations, potentially leading to better patient outcomes, reduced healthcare costs, and a better quality of life for individuals around the world.
- Organogenesis Holdings Inc. reported strong financial results for Q4 and full year 2024, with a total revenue of $128.1 million and $459.9 million, respectively.
- The company’s net income for Q4 and full year 2024 were $15.5 million and $33.9 million, respectively.
- The Advanced Wound Care segment saw a 14.8% year-over-year growth in sales, while the Surgical and Sports Medicine segment reported a 3.7% growth.
- These financial results indicate ongoing success and growth in the regenerative medicine industry, which could lead to improved healing times, reduced scarring, and more effective treatments for various injuries and conditions.
- The global healthcare industry could benefit from Organogenesis’ commitment to research and development in tissue innovations, potentially leading to better patient outcomes, reduced healthcare costs, and a better quality of life for individuals around the world.
